Analgesic Effect and Safety of Oliceridine and Oxycodone in Vitrectomy (NCT07097038) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Analgesic Effect and Safety of Oliceridine and Oxycodone in Vitrectomy
120 participantsStarted 2025-07
Plain-language summary
Traditional opioid analgesia is a method to treat moderate to severe pain. However, the use of opioids is not without risks. When treating acute pain, patients may have hypotension, respiratory depression, hypoxia, nausea and vomiting, irritability and pruritus. The aim of this study was to evaluate the analgesic effect and safety of g-protein-biased μ - opioid receptor agonists Oliceridine and oxycodone in vitrectomy.
Who can participate
Age range
18 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age 18-75 years old, ASA Ⅰ - Ⅱ (the age of patients with vitreous surgery can be relaxed to 75 years old, and serious systemic diseases need to be excluded);
* Vitrectomy with local anesthesia (retrobulbar / peribulbar block) combined with intravenous sedation and analgesia (such as maculopathy, retinal detachment, etc.);
* Preoperative VAS score ≤ 3, can cooperate with pain and sedation score;
* Signed informed consent.
Exclusion Criteria:
* Be allergic to test drugs or opioids, or have a history of opioid abuse;
* Severe cardiopulmonary disease (such as heart failure, COPD), liver and kidney dysfunction (alt/ast \> 3 times normal, creatinine \> 177 μ mol/l);
* Glaucoma (avoiding the risk of fluctuation of intraocular pressure), sinus bradycardia (\< 50 beats / min, preventing aggravation of oculo cardiac reflex);
* Used analgesic / sedative drugs within 24 hours before surgery;
* Those who are unable to cooperate due to mental illness or cognitive impairment.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
VAS score 2 hours after operation
Timeframe: From enrollment to the end of treatment at 1 day